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Peptide mimics of intracellular loop 2 (ic2) of the human 5HT1a receptor have been studied with respect to their ability
to inhibit agonist binding via interference with receptor-G-protein coupling. These peptides give shallow concentration-eﬀect
relationships. Additionally, these peptides have been studied with respect to their ability to trigger the signal transduction system
of this Gi-coupled receptor. Two signaling parameters have been quantiﬁed: concentration of intracellular cAMP and changes in
incorporationintotheGproteinofastableanalogofGTP.Inbothcases,peptidemimicsnearmidloopofic2actuallyshowagonist
activitywitheﬃcacy falling oﬀ towardboth looptermininear TM3 andTM4. Previousresultshave suggested thatthe loopregion
near the TM3/ic2 interface is primarily responsible for receptor-G-protein coupling, while the current result emphasizes the mid-
ic2 loop region’s ability to activate the G protein following initial coupling. A limited number of peptides from the receptor’s
TM5/ic3 loop vicinity were also studied regarding agonist inhibition and G-protein activation. These peptides provide additional
evidence that the human 5HT1a receptor, TM5/ic3 loop region, is involved in both coupling and activation actions. Overall,
these results provide further information about potential pharmacological intervention and drug development with respect to
the human 5HT1a receptor/G-protein system. Finally, the structural evidence generated here provides testable models pending
crystallization and X-ray analysis of the receptor.
1.Introduction
Regulation of serotonergic (5-hydroxytryptamine; 5HT)
function in animals impacts numerous physiological and
pathological processes [1] .5 H Ti sb r o a d l yr e p r e s e n t e di nb i -
ological systems as a regulator and modulator via nervous,
hormonal, and autacoidal means [2–5]. For example, sero-
tonin [6] has been implicated in the pathophysiology of
migraine.Thisassociationwithmigraineissharedwithmany
other factors including adipokines such as leptin; hypothala-
mic hormones, Orexin A and B (also known appetite regula-
tors as is 5HT); numerous neurotransmitters [7]; autacoids;
hormones, and ions like calcium, and magnesium. The
range of biological molecules that interact with serotonergic
processes suggests that various signaling pathways may be
shared, and that the potential for dynamic, collaborative
regulationexists.Betterunderstandingofthemolecularbasis
underlying these signaling processes is not only critical to
greater fundamental knowledge but to therapeutic develop-
ment.
Various receptors (R), including the 5HT3R’s that are
ligand-controlled ion channels, are crucial to these regula-
tory processes [4]. All other known 5HTR’s are structurally
diﬀerent than these ion channels, being serpentine mem-
brane R’s [8], coupled (C) to the cells interior by G (GTP
binding) proteins (P), which in turn regulate key eﬀectors
such as adenylyl cyclase (AC, [9]). These GPCR’s share the
structural characteristic of 7-transmembrane (7TM) helical
segments [10–13]. For many years, the only crystal structure
was of rhodopsin, the prototype GPCR, in its interaction
with the G-protein transducin [14]. Recently a breakthrough
has occurred, with crystallization of the beta-adrenergic
receptor (BAR) and publication of X-ray structures [15–
18]. This long-awaited event has set the stage for other
GPCR.Progressivedevelopmentshavebeendemonstratedby
crystal structures for the adenosine A2R [19], the CXDR42 International Journal of Peptides
chemokine R [20], and the dopamine D3R [21]. Crystal
structures for other GPCR, including that those 5HTR’s that
are GPCR’s should soon follow [22].
OftheGPCRrecognizedas5HTR,the5HT1aR(arelative
of BAR) is one of the most highly studied [23–25], and
it has been associated with physiological and pathological
processesasdiverseasthermoregulation,cognitiveﬂexibility,
and control of mood [26–33]. Depression, underlying anxi-
ety disorders, and related psychopathologies are a particular
theme [34–39]. Multiple strategies have been used to dissect
the complex pathways underscoring these physiological
and pathological processes [40–47]. One approach centers
around analysis of allosteric sites of action on receptors.
Peptide mimics of intracellular loop regions of 5HT1aR have
been used as probes of the receptor-G-protein interface in
this context [48–54]. The current communication continues
ouranalysiswiththesepeptideprobesparticularlyemphasiz-
ing intracellular loop 2 (ic2) with some, limited comparative
data from intracellular loop 3 (ic3). The results with ic2
and ic3 are suggestive of potential sites for regulation and
therapeutic drug development.
2.MaterialsandMethods
2.1. Cell Culture. Chinese Hamster ovary (CHO) cells ex-
pressingtheH5-HT1aR[55,56]w er ecultur edinH am ’ sF -12
medium fortiﬁed with 10% fetal calf serum and 200ug/mL
geneticin. Cultures were maintained at 37◦C in a humidiﬁed
atmosphere of 5% CO2. Cells were subcultured or assayed
upon conﬂuency (5–8 days). Cloned H5-HT1aR was kindly
provided by Dr. John Raymond (Medical U. of South
Carolina; [41]). The cell line has been tested for mycoplasma
with a PCR kit (ATCC) and is free of contamination.
2.2. Receptor Preparation. Cells were trypsinized and cen-
trifuged at low speed in ice-cold medium [53]. The pellet
was resuspended in ice-cold Earle’s Balanced Salt Solution
followed by centrifugation. Cells were resuspended in 10mL
of ice-cold binding buﬀer(50mMT ris,4mMCaCl 2,1 0μM
pargyline, and pH 7.4), homogenized with Teﬂon-glass, and
centrifugedfor450,000g-min.at4◦C.Foracrudemembrane
preparation, the pellet was resuspended in 30mL of ice-cold
binding buﬀer, homogenized on Teﬂon-glass and then by
Polytron (setting 4) for 5 seconds, and stored on ice and
assayed within the next 1.5 hours [54].
2.3. Assay of Receptor Activity. Binding of the agonist [3H]8-
OH-DPAT ([3H]8-hydroxy-2-(di-n-propylamino)tetralin)
to H5-HT1aR followed well-characterized protocols
[49,50,53].RadioligandswerepurchasedfromNewEngland
Nuclear (NEN), Boston, MA, and 1mL reaction mixtures,
in triplicate, were incubated for 30min. in a 30◦C shaker.
The 1mL mixture was 700μLo fr e c e p t o rp r e p a r a t i o n ;
100μL of binding buﬀer (for total binding) or 10μM 5-HT
(for nonspeciﬁc binding), 100μL of the tritiated agent
(concentration of 0.5nM [3H] 8-OH-DPAT), and 100μLo f
peptide or binding buﬀer in the case of controls.
Reactions were stopped by addition of 4mL of ice-cold
50mM Tris buﬀer, pH 7.4, and vacuum ﬁltration on glass
ﬁber ﬁlters (Whatman GF/B). Filters were rinsed twice in
5mL of ice-cold Tris buﬀer, dried, and counted in 5mL of
Ecoscint (National Diagnostics) liquid scintillation ﬂuid in a
Beckman LS 6500. Homogenates were assayed for protein to
maintain a nominal value of 50μg protein per ﬁlter [57]. All
tubes were run in triplicate.
2.4. cAMP Assay. CHO cells were cultured to conﬂuency in
12- or 24-well plates. Medium was aspirated, and the cells
were rinsed twice in warm, serum-free F-12 medium. Cells
were incubated for 20min. at 37◦Ci n0 . 5m l so fs e r u m - f r e e
F-12 medium containing 100uM isobutylmethylxanthine
(IBMX) and the following substances (ﬁnal concs.) alone or
in combination (see Figures 3 and 5): 30μM forskolin (FSK;
for all treatments); 1μM 5-HT; peptide concentrations as
notedinﬁgurelegends.Reactionswerestoppedbyaspiration
of medium and addition of 0.5mL of 100mM HCl. After
10min., well contents were removed and centrifuged at
4000rpm. Supernatants were diluted in 100mM HCl, and
cAMP was quantiﬁed [53] directly in a microplate format by
enzyme immunoassay (EIA) with a kit from Assay Designs
(Ann Arbor). Triplicate-independent samples were assayed.
2.5. [35S]GTPγS Assay. H5-HT1aR membranes from trans-
fected CHO cells were incubated with 5-HT (0.1μM) and/or
peptide concentrations as noted in ﬁgure legends (see
Figures 2 and 4) and the following incubation mixture:
20mM HEPES buﬀer, pH 7.4, 5mM MgCl2,1m ME D T A ,
1mM DTT, 100mM NaCl, 100uM GDP, 10μM pargyline,
0.2mM ascorbate, and 0.1nM [35S]GTPγS[ 53, 58]. Mix-
tures were incubated for 30min. at 30◦C, and were terminat-
ed by dilution in cold buﬀer. The mixture was ﬁltered on
GF/C ﬁlters, rinsed twice in buﬀer, dried and counted by
liquid scin-tillation. All values reported in are for speciﬁc
binding (total nonspeciﬁc) of triplicates. Nonspeciﬁc bind-
ingwasdeterminedinthepresenceofcoldγ-S-GTP(10uM).
N e g a t i v ec o n t r o li st h ea b o v em i x t u r em i n u st e s td r u go r
5HT. Positive control contains 5HT.
2.6. Data Analysis. All statistics (means, standard errors of
the mean (SEM), t tests and ANOVA, Pearson correlation
coeﬃcients (r), and graphical procedures (including drug-
receptor-binding analysis) were conducted with PSI-Plot
(Version 8) software (Poly Software International), Prism
(version 4.0c), or using a Hewlett-Packard Graphing Calcu-
lator, HP48. The apriori was α = 0.05 for all experiments.
Experiments were conducted with a minimum of n = 3, in
triplicate. Most experiments were n = 3–5. In some cases
(indicated in ﬁgure legends), diﬀerent n’s and multiplicates
were used.
2.7. Peptide Preparation. These highly puriﬁed (greater than
95%) peptides were purchased from New England Peptide
LLC. The peptides are segments of ic2 and ic3 of the cloned
H5HT1aR. Peptides stored at −20◦C were initially dissolved
in deionized water. Subsequent dilutions were in bindingInternational Journal of Peptides 3
Table 1: ic2 and ic3 peptide mimics. The primary amino acid seq-
uences for the H5HT1aR ic2 loop peptide mimics P11 and P’s 21–
27, and for ic3 (P1, P12, and P13). The receptor’s amino terminal is
to the left. Sequences for H5HT1aR from Kobilka et al., 1987 [56].
P11 is from a previous study by Thiagaraj et al., 2007 [53], and
P1 from Hayataka et al., 1988 [49] (both included for comparative
purposes).
P11 IALDRYWAITD
P21 LDRYWAITDP
P22 RYWAITDPID
P23 WAITDPIDYV
P24 ITDPIDYVNK
P25 DPIDYVNKRT
P26 IDYVNKRTPR
P27 YVNKRTPRPR
P1 IFRAARFRIRKTVKK
P12 KTVKKVEKTG
P13 VKKVEKTGAD
buﬀer. The peptides examined in this study are listed in
Table 1.
3. Results
3.1. Intracellular Loop 2 (ic2). T h es i z eo fH 5 H T 1 a ’ si c 2
(about20aminoacids)makesitatemptingtargetforanalyz-
ing the loop’s coupling to and activation of Gi [23, 24]. Our
previous work with ic2 emphasized the N-terminal region of
the loop with a peptide we call P11 (Table 1). Results with
this peptide suggest that the loop residues near TM 3 are
vital for coupling of the loop to Gi but are not involved in G-
p r o t e i na c t i v a t i o n[ 53]. Results from the Varrault group [48]
looked at the entire loop without distinguishing subregions;
their conclusions were that the entire loop is responsible
for activation (they did not diﬀerentiate between coupling
and activation). The following question arises: can coupling
and activation characteristics be identiﬁed for the loop
on a subregional basis? Our preliminary work at the N-
terminal aspect of H5HT1a’a ic3 suggested to us that the
techniques we use could be productive in addressing such a
question [49, 50, 53]. Thus, we synthesized peptides of 10
residues each that progress from the N-terminus of ic2 to
the C-terminus two amino acids at a time (Table 1). Beyond
the parent peptide, P11, this results in seven additional
peptides (P21–P27). Agonist inhibition [59, 60]w a su s e d
as a measure of coupling eﬃcacy. Any agent or process that
uncouplesareceptorfromitsG-proteinpartnerincreasesthe
probability that the receptor will be in a lower aﬃnity state
for agonist binding. This results in concentration-dependent
agonist dissociation relationships that reﬂect aﬃnity of the
uncoupler for the G protein (and potentially by analogy
the aﬃnity of the cognate receptor loop region for the G
protein). Two determinants of G-protein activation (stable
GTP binding to Gi and changes in intracellular cAMP
concentration) were used to monitor a peptide’s ability to
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Figure 1: P21 noncentration-dependent displacement of bound 8-
OH-DPAT. This curve represents the change in speciﬁc binding of
[3H]-8-OH-DPAT, a 5HT1aR agonist, to the receptor in the pres-
ence of various concentrations of the ic2 peptide mimic P21. Nom-
inal binding of agonist at control levels was 400fmoles/mg protein.
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Figure 2: ic2 peptide eﬀect on γ-[35S]-GTP incorporated into Gi,
a measure of G-protein activation. Control is the basal amount
of γ-[35S]-GTP incorporated into Gi in CHO cells expressing
the human 5HT1aR, set as 100%. The Y- a x i si st h ep e r c e n to f
speciﬁcally bound (total minus nonspeciﬁc) γ-[35S]-GTP. All other
treatments are percents of the control value. All peptides are 30uM
concentration and 5HT 10−7 M concentration. Error is expressed as
SEM.
perturb G protein following coupling. The overall results for
these eight peptides are in Table 2.
As shown in Figure 1 with results from peptide P21 as
an example, these peptides give shallow concentration-eﬀect
curves for the measure of coupling and agonist inhibition.
Similar experiments with all peptides form the basis for
the summarized coupling results found in Table 2.N o t e
that limited peptide solubility and lack of eﬃcacy prevented
complete IC50 determination for all peptides (P24–27). The
uM concentration ranges for activity of these peptides, and,
shallow concentration-eﬀect relationships in, are typical for
other peptides we and others have analyzed [48, 53].
Figure 2 gives results for the eight peptides’ ability to
foster incorporation of GTP into Gi using a radioactively
labeled, reasonably stable form of GTP ([35S] gamma-S-
GTP). Relative to control (buﬀer alone; no agonist nor
peptide) midloop residues as represented by peptide P23 are
most eﬀective in directing incorporation of GTP into Gi.
Eﬃcacy declines in both N- and C-terminal directions from
P23althoughtheresultsforP21areanomalousinthisregard.
ItisnotclearwhetherthisresultforP21ismeaningfulordue
to experimental error although the results for intracellular4 International Journal of Peptides
Table 2: ic2 Peptide mimic eﬀect on [3H]8-OH-DPAT binding. All binding inhibition values are percent of control agonist (ag.) bound. The
upper portion of the table is for peptides nearer the C-terminus, including P11 from Thiagaraj et al., 2007 [53]. These peptides decreased
the speciﬁc high aﬃnity binding of 5HT1aR agonist [3H]-8-OH-DPAT by 50% at the given concentration. The lower portion of the table
( P 2 4o n )i st h ei c 2p e p t i d e st o w a r dt h eCt e r m i n u s .T h e s ep e p t i d e sw e r el e s se ﬀective at decreasing speciﬁc high aﬃnity binding of [3H]-8-
OH-DPAT, and values given are percent of control at the given concentration. Values for intracellular cAMP are relative to FSK-stimulated
control. All values for incorporation of γ-[35S]-GTP into Gi are percent of control. Nominal values for control binding were 400fmoles/mg
protein.
Peptide Conc. (uM) % cont. ag, bound, (SEM) [cAMP] (SEM) GTP Incorp. (SEM)
Control 100 (6) 100 (7)
5HT 21 (4) 168 (12)
P11 7 50 (1) 87 (8) 100 (3)
P21 15 52 (4) 122 (8) 158 (11)
P22 16 51 (2) 71 (2) 128 (9)
P23 30 50 (22) 42 (4) 188 (10)
P24 10 94 (9) 45 (7) 146 (17)
P25 30 87 (12) 64 (3) 126 (10)
P26 30 75 (19) 100 (5) 111 (9)
P27 30 95 (5) 132 (6) 130 (7)
Peptide effect on forskolin (FSK) stimulated cAMP 
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Figure 3: ic2 peptide eﬀect on forskolin-stimulated cAMP pro-
duction, a measure of activated-G-protein regulation of adenylyl
cyclase. Forskolin (FSK) stimulated cAMP production by adenylyl
cyclase (AC) is in CHO cells expressing the human 5HT1aR. FSK
(30uM)isthecontrol,whichissetto100%.Allothertreatmentsare
expressed as a percent of the control value. Peptide concentrations
are 30uM. All treatments include isobutylmethylxanthine (IBMX)
an inhibitor of the metabolism of cAMP by phosphodiesterase.
E r r o ri se x p r e s s e da sS E M .
cAMP (Figure 3) may shed some light on this situation. Note
that GTP binding by Gi is an agonist-dependent process
(see 5HT in the Figure); thus, when peptides increase GTP
incorporation above control level, the implication is that
the peptides are representing native loop regions under the
inﬂuence of agonist.
Figure 3 shows a parallel set of results whereby the
peptides’abilitytochangeintracellularcAMPconcentrations
following coupling to Gi is determined (control is the FSK
stimulated level; agonist; e.g., 5HT activates Gi and lowers
cAMP levels below the control reading). Again, peptide P23,
representing mid-loop residues, is most eﬀective. In contrast
to the results for GTP incorporation in Figure 2, the cAMP
results have a smooth drop oﬀ in eﬃcacy on both sides
of P23. Overall, the trends peaking at P23 and declining
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γ-[35S]-GTP incorporation for P12 and P13
Figure 4: P12 and P13-stimulated incorporation of γ-[35S]-GTP
control is the basal amount of γ-[35S]-GTP incorporated into Gi in
CHO cells expressing the human 5HT1aR set as 100%. The Y axis is
the percent of speciﬁcally bound γ-[35S]-GTP. All other treatments
are percents of the control value. Peptide concentrations are 30uM.
∗P<0.01 P12 versus control; CP<0.01 5HT versus 5HT/P12.
∗P13 versus control P<0.01; C5HT versus 5HT/P13 P<0.01.
on both sides are parallel for GTP incorporation (Figure 2)
and cAMP concentrations (Figure 3). Note that basal levels
of intracellular cAMP are quite low, and the experimental
protocol for these experiments involves artiﬁcially raising
cAMP concentrations via stimulation of adenylyl cyclase
with forskolin (control) and comparison of peptide results
to that produced by the agonist serotonin.
3.2. Intracellular Loop 3 (ic3). H5HT1aR’s ic3 is much larger
than ic2 (about 130 amino acids); nevertheless, we did a veryInternational Journal of Peptides 5
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Figure 5: P12 and P13 eﬀect of forskolin-stimulated cAMP pro-
duction forskolin (FSK) stimulated cAMP production by adenylyl
cyclase (AC) in CHO cells expressing the human 5HT1aR. These
experiments were a measure of second messenger regulation by
G protein. FSK is the control, which is set to 100%. All other
treatments are expressed as a percent of the control value. Peptide
concentrations are 30uM. All treatments include isobutylmethyl
xanthine (IBMX), an inhibitor of the metabolism of cAMP. 5HT
versus 5HT/P12 and 5HT versus 5HT/P13 ∗P<0.05.
limited number of comparisons at the N-terminal (TM5)
region of ic3, continuing preliminary work [50–53]a n d
using the same approach as with ic2 by synthetically building
10-MER’s two amino acids at a time from the parent (P1;
Table 1). Table 3 gives coupling and activation summaries
for the two peptides, P12 and P13 (Table 1). As with the
ic2 peptides, the ic3 peptides, P12 and P13, give shallow,
uM concentration-eﬀect relationships (data not shown
in graphical form as in Figure 1). For coupling, if 50%
is listed, then that is the IC 50; if another value is listed,
that is the maximum inhibition possible with the highest
soluble concentration. Both P12 and P13 produce small
but signiﬁcant incorporation increases of GTP based upon
the amount of [35S]-GTP incorporated into Gi (Figure 4),
while the outcomes for changes in intracellular cAMP
concentrationsaremorecomplex(Figure 5):forpeptideP12,
intracellular cAMP concentration is not altered; unusually,
peptide P13 actually increases intracellular cAMP concen-
tration. A possible explanation for the combined results for
P12 and P13 is given in the Discussion section.
4. Discussion
H5HT1aR is linked to numerous important physiological
and pathological processes. Additionally, the receptor is a
close relative, not only of other 5HT1 type receptors, but
also the beta adrenergic receptors and other GPCR’s [13, 42,
55, 56]. Because of these characteristics, structural determi-
nations of the receptor are crucial matters. Despite recent
criticalstructuraladvanceswiththebetaadrenergicreceptors
[10, 15, 16, 18], the 5HT1aR is uncrystallized and its struc-
ture awaits X-ray analysis [22].
In previous work [49, 50, 53, 54], we have demonstrated
the utility of an agonist-based inhibition system associated
with signal transduction parameters to study interactions
of the receptor with its cognate G protein, Gi. In the
Table 3: ic3 Peptide mimic coupling and signal transduction data.
Summary of data generated for all ic3 experiments with P12 and
P13. P1 is included as a reference, from Hayataka et al., 1998 [49].
Nominal values for control agonist binding were 400fmoles/mg
protein.
Peptide Agonist (%)
inhibition
[35S]-γ-S-GTP
incorporation%
above conro
% Inhibition of
FSK-stimulated
cAMP
P1∗ 50 (3uM) 30 (1uM) 10 (10uM)
P12 28 (30uM) 24 (30uM) 0 (30uM)
P13 50 (15uM) 12 (30uM) −24 (30uM)
current investigation we have presented further information
abouttheH5HT1aR/Giinterfacethatshouldprovidetestable
hypotheses anticipating the ultimate structural analysis of
the receptor.
Data collected in previous and current experiments
have implicated a role for ic2 in receptor coupling and G-
protein activation. The N-terminus end of ic2, involving
the sequence IALDRYWAITDPIDYV and including pep-
tides P11 (previous work) and P21–P23 (current work), is
important for coupling to the G protein. Evidence for this
includes presence of the highly conserved DRY sequence
for GPCR’s [51] and from the present study, IC50’s for the
peptides’ coupling capacity, with ranges from 7 to 30uM.
Decay of G-protein coupling activity was observed as the
peptides progress towards the C-terminus of ic2 (P24–
27). As the amino acids seem to wane in importance for
receptor coupling, they increase for part of the distance in
importance for G-protein activation with its peak at the
P23 amino acid stretch WAITDPIDYV. This is clearly shown
by the bell-shaped progression of the data bars for the
incorporation of γ-[35S]-GTP into Giα (Figure 2). This can
be superimposed over the inverted bell-shaped depression
for intracellular levels of FSK-stimulated cAMP production
(Figure 3) following peptide treatment.
The C-terminal end of ic2 consisting of the amino
acids RTPRPR may serve as an anchor, helping to hold the
amino terminal of ic2 in a favorable orientation for coupling
to the G protein [48]. Also interesting about the carboxy
terminal end of ic2 is the presence of the 2 proline (P)
residues separated by only 1 amino acid. These proline
residues in close proximity to each other introduce a kink
in the receptor structure constraining its range of motion.
These data demonstrates the clear role for H5HT1aR’s ic2 in
couplingreceptortoGprotein,andtowardtheloop’smiddle,
G-protein activation.
For ic3, the inhibition of AC by Gi is an important
regulator of intracellular signal transduction. The current
peptides tested, P12 and P13, diﬀered in their ability to
regulate this step in the cascade. P12 was unable to decrease
the FSK-stimulated levels of cAMP (Figure 5). This is in
contrast to the action of 5HT which was able to signiﬁcantly
decrease the FSK-stimulated levels of cAMP. P13 had the
opposite eﬀect; it increased cAMP concentrations (Figure 5)!
This suggests that the two new amino acids (AD added to6 International Journal of Peptides
form P13) from ic3 are potentially at the beginning of a
region of the loop which has negative regulatory properties
on Gi blunting its normal ability to regulate AC. It is
interesting to speculate about the diﬀerences in data from
the γ-[35S]-GTP (Figure 4) incorporation assays and cAMP
assays (Figure 5). P12 slightly increases GTP incorporation
while P13 statistically does not. Thus, P12 activates Gi but
cAMP changes do not ensue. P13 does not activate Gi,
but a cAMP change occurs in the atypical direction. With
the relatively small changes produced by these two peptides
in both signaling measures, one possibility is experimental
error that has not been accounted for. It is possible that the
peptides are acting at some sites other than the proposed
receptor-G-protein interface or that the process at the inter-
face is more complex.
Themosttantalizingpossibilityisthatthenewlyexplored
region represented by P12 and P13 is the beginning of a
region of ic3 involved in coupling of receptor to G protein
still capable of regulating Gi. Additionally, the perturbation
of Gi in this case involves diﬀerent conformational changes
that activate Gi but in a novel way. This would produce
the opposite eﬀect on cAMP concentration and would be
equivalent to the downstream actions of an inverse agonist at
the ligand binding site. Since 5HT1aR is capable of constitu-
tive activity [25], inverse agonism is possible, and it will be
fascinating to see if the P12/P13 region is involved in this
activity once the crystal structure is available. In this context
then, P12 would represent a transitional region between
“normal” and “atypical” Gi regulation while P13 is in the
atypical subregion.
While the data support this region’s (P12/P13) role in
receptor-G-protein coupling, the peptides’ ability to uncou-
ple declines relative to previously studied peptides whose
structures represent segments closer to ic3’s N-terminus.
P12 and 13 are beyond (toward the C-terminus) the key
RFRI region of P1 previously identiﬁed as key to that
part of 5HT1aR’s ic3-N-terminus responsible for G-protein
activation [50].
Varrault et al. [48] demonstrated that the C-terminal
sectionofi3isinvolvedinGproteincouplingandregulation.
So,ifourworkcanbeinterpretedtomeanthatpeakcoupling
andactivatingpropertiesareassociatedwithic3’sN-terminal
residues and Varrault’s work can be interpreted to mean that
peak coupling and activating properties are associated with
ic3’sC-terminalresidues,thenwhatrolewillholdforthevast
internal region of the loop in 5HT1aR? GPCR ic3’s are vari-
able in size in rhodopsin versus 5HT1aR and BAR’s, which
have larger ic3 loops (at least twice the size of rhodopsin’s
ic3). It would be meaningful to extend this peptide approach
into the midloop region of H5HT1a’s ic3, and then as a crys-
tal structure becomes available the comparisons of 5HT1aR
loop function with BAR and rhodopsin will be fascinating.
Neither of the peptides (P12 and P13) are as potent
as 5HT at incorporating GTP into Giα. It is possible that
multiple regions are responsible for G-protein activation,
and the individual peptides mimic only part of this structure
[61], thereby producing a diminished eﬀect relative to 5HT.
Also, a given peptide region, even one that is absolutely
critical in the native structure, may not have the most
eﬃcacious tertiary structure without the full loop being
present. It is crucial to point out that the parent ic3 peptide
(P1) contains the full TVKK sequence at its N-terminus.
This sequence is part of the so-called Ric-8 [62, 63]r e g i o n
that has been shown in other GPCR as crucial to G-protein
regulation. Signiﬁcantly, the P1 relatives (P12 and P13)
under discussion in this communication are at a transition
point for this sequence; P12 contains the full TVKK stretch
while P13 has lost the T! One additional observation may
be pertinent. For GTP incorporation, for both peptides, the
combination of peptide plus 5HT produces markedly greater
incorporation than that produced by 5HT alone. This
may suggest that 5HT and the peptides may be perturbing
separate sites on the receptor and/or G protein.
In summary, this peptide mimic study for intracellular
loops 2 and 3 of the H5HT1aR was designed to examine
which segments were involved in coupling and activation
of Gi. The results reported here in combination with
previously reported work conclude that the amino terminal
ends of ic2 and ic3 are important for coupling the receptor
and G protein. The activation of G-protein peaks at P23
(WAITDPIDYV) in ic2 (mid-loop). The activity is decreased
as the structures move in either direction away from this
core sequence. The curious results of increased cAMP
concentrations caused by P13 suggests that the two new
amino acids (AD) in P13 are the beginning of a new region
of ic3 which has negative regulatory properties on Gi. That
is, the new region may be one that is not normally activated
by agonists; however, in the presence of inverse agonists and
the diﬀerent conformational changes they produce, the new
region may couple to and activate Gi in a way that regulates
AC in a way we deﬁne as inverse agonism. The combined
results with H5HT1aR ic2 and ic3 peptides should lead
to testable crystallographic hypotheses with drugs having
diﬀerential intrinsic activities. Beyond the ﬁnal judgment of
these peptide probes in the structural sense, the information
produced may be useful as independent pharmacological
observations. Pragmatic implications of the work may be
relevant in a framework where the multiple, diﬀerential
activities of the peptides can be used by medicinal chemists
to build unique pharmacological agents targeting unutilized
sites at the receptor-G-protein interface.
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